Results for this period
Full year1 June 2025 to 31 May 2026Non-consolidated (standalone)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
In the pharmaceuticals business, growth in demand for existing products, higher sales of imported active pharmaceutical ingredients and strong sales of new products contributed to results. In the health foods business, orders for OEM jelly products remained solid, while the cost ratio improved as factory utilization remained high. In the chemicals business, results benefited from an active semiconductor market, expansion into the power industry market and demand related to AI data centers. Meanwhile, an impairment loss of ¥398.585 million was recognized on property, plant and equipment following a revision of the sales outlook for certain contract-manufactured products.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 June 2025 to 31 May 2026 |
| Net Sales | ¥7,840 million (YoY +17.9%) |
| Operating profit | ¥742 million (YoY +71.9%) |
| Ordinary income | ¥707 million (YoY +64.5%) |
| Profit attributable to owners of the parent | ¥163 million (YoY -32.4%) |
| Net income per share | ¥40.58 |
| Operating Margin | 9.5% |
| Equity ratio | End of the current fiscal period 40.6 / End of previous period 46.6 |
| Total assets | ¥6,352 million |
| Net assets | ¥2,576 million |
| Cash flows from operating activities | ¥808 million |
| Cash flows from investing activities | ¥-237 million |
| Cash flows from financing activities | ¥317 million |
| Cash and cash equivalents at end of period | ¥1,917 million |
| Full-year earnings forecast | Net Sales ¥7,100 million (YoY -9.4%) / Operating profit ¥550 million (YoY -26.0%) / Ordinary income ¥500 million (YoY -29.3%) / Net income ¥350 million (YoY +114.7%) |
| Annual Dividend Forecast | ¥26 → ¥26（0.0%） |
| Payout ratio | 64.1 |
| Segment revenue | Pharmaceuticals Business ¥3,985.76 thousand (YoY +23.9%), Health Food Business ¥1,185.95 thousand (YoY +13.7%), Chemicals Business ¥2,669.23 thousand (YoY +11.6%) |
| Segment profit | Pharmaceuticals Business ¥633.81 thousand (YoY +33.8%), Health Food Business ¥17.79 thousand, Chemicals Business ¥91.33 thousand (YoY +59.7%) |
| Depreciation and amortization | ¥191,017 thousand |
| Impairment loss | ¥398,585 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥20,500 thousand / Extraordinary loss Loss on Disposal of Fixed Assets ¥1,274 thousand, Impairment Losses ¥398,585 thousand |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Material subsequent events | No applicable matters. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Available (for institutional investors and analysts) |
| Issued Shares at Period-End | 4,095,500 Shares |
| Treasury Shares at Period-End | 70,426 Shares |
| Factors Behind Changes in Business Performance | In the pharmaceuticals business, growth in demand for existing products, higher sales of imported active pharmaceutical ingredients and strong sales of new products contributed to results. In the health foods business, orders for OEM jelly products remained solid, while the cost ratio improved as factory utilization remained high. In the chemicals business, results benefited from an active semiconductor market, expansion into the power industry market and demand related to AI data centers. Meanwhile, an impairment loss of ¥398.585 million was recognized on property, plant and equipment following a revision of the sales outlook for certain contract-manufactured products. |
Items this document does not state (5)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the pharmaceuticals business, growth in demand for existing products, higher sales of imported active pharmaceutical ingredients and strong sales of new products contributed to results. In the health foods business, orders for OEM jelly products remained solid, while the cost ratio improved as factory utilization remained high. In the chemicals business, results benefited from an active semiconductor market, expansion into the power industry market and demand related to AI data centers. Meanwhile, an impairment loss of ¥398.585 million was recognized on property, plant and equipment related to the pharmaceutical synthesis business following a revision of the sales outlook for certain contract-manufactured products.